MARK2 and thyrotoxicosis: Furthermore, Xie et al. revealed higher SIRI values in B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation in patients with papillary thyroid carcinoma [82], while He et al. integrated SIRI in a formula to distinguish SAT patients with thyrotoxicosis from Graves disease patients [73].